GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (OTCPK:SHEZF) » Definitions » Total Assets

Shenzhen Hepalink Pharmaceutical Group Co (Shenzhen Hepalink Pharmaceutical Group Co) Total Assets : $2,621.0 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Total Assets?

Shenzhen Hepalink Pharmaceutical Group Co's Total Assets for the quarter that ended in Mar. 2024 was $2,621.0 Mil.

During the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co's average Total Assets Growth Rate was -6.70% per year. During the past 3 years, the average Total Assets Growth Rate was 3.00% per year. During the past 5 years, the average Total Assets Growth Rate was 7.80% per year. During the past 10 years, the average Total Assets Growth Rate was 17.70% per year.

During the past 13 years, Shenzhen Hepalink Pharmaceutical Group Co's highest 3-Year average Total Assets Growth Rate was 102.30%. The lowest was 3.00%. And the median was 18.70%.

Total Assets is connected with ROA %. Shenzhen Hepalink Pharmaceutical Group Co's annualized ROA % for the quarter that ended in Mar. 2024 was 3.24%. Total Assets is also linked to Revenue through Asset Turnover. Shenzhen Hepalink Pharmaceutical Group Co's Asset Turnover for the quarter that ended in Mar. 2024 was 0.07.

Shenzhen Hepalink Pharmaceutical Group Co Total Assets Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Total Assets Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,188.85 2,909.47 3,000.04 2,985.79 2,689.48

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,992.79 2,902.71 2,757.03 2,689.48 2,620.98

Shenzhen Hepalink Pharmaceutical Group Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Shenzhen Hepalink Pharmaceutical Group Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=1678.998+1010.481
=2,689.5

Shenzhen Hepalink Pharmaceutical Group Co's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=1685.553+935.424
=2,621.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co  (OTCPK:SHEZF) Total Assets Explanation

Total Assets is connected with ROA %.

Shenzhen Hepalink Pharmaceutical Group Co's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=86.116/( (2689.479+2620.978)/ 2 )
=86.116/2655.2285
=3.24 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Shenzhen Hepalink Pharmaceutical Group Co's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=190.69/( (2689.479+2620.978)/ 2 )
=190.69/2655.2285
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Shenzhen Hepalink Pharmaceutical Group Co Total Assets Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (Shenzhen Hepalink Pharmaceutical Group Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (OTCPK:SHEZF) » Definitions » Total Assets
Comparable Companies
SZSE:300363 SZSE:301015 SZSE:002773 SHSE:600422 SZSE:002317 SZSE:002675 SHSE:600062 SZSE:300199 SHSE:688192 SZSE:002737 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
09989:Hong Kong 002399:China
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Website
https://www.hepalink.com
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Shenzhen Hepalink Pharmaceutical Group Co (Shenzhen Hepalink Pharmaceutical Group Co) Headlines

From GuruFocus

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

By PRNewswire PRNewswire • 03-28-2023